Radius Recycling, Inc. (RDUS)
(Delayed Data from NSDQ)
$17.14 USD
+0.05 (0.29%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $17.15 +0.01 (0.06%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
Brokerage Reports
0 items in cart
[RDUS]
Reports for Purchase
Showing records 41 - 60 ( 169 total )
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
Quietly Moving Towards Profitability by Growing the Tymlos Brand; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Industry: Medical - Drugs
Changes to our Model Ahead of 4Q20 Earnings; Reiterate Neutral, Increase Price Target to $25
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
Radius Acquires CBD Asset and Issues Stronger Than Expected Financial Guidance; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
Tymlos Shows Encouraging Signs as Radius Begins Execution on Its New Strategy; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Industry: Medical - Drugs
Model Update Ahead of 3Q; Reiterate Neutral, Target to $22
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
RAD 140 Divesture Hones Radius? Focus on Core Endocrinology Business; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Industry: Medical - Drugs
Reorganization Signals More Proactive Radius; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
Completion of wearABLe Is Milestone as Key Readout Looms in 2021; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department